U.S.
Securities and Exchange Commission
Washington
D.C. 20549
FORM
10-QSB/A2
(Mark
One)
[
X ] QUARTERLY REPORT PURSUANT TO SECTION 13
OR
15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the
quarterly period ended March 31, 2005
[
] TRANSITION REPORT UNDER SECTION 13 OR 15(d)
OF
THE EXCHANGE ACT
For the
transition period from
to
Commission
file number
0-12183
BOVIE
MEDICAL CORPORATION
(Exact
name of small business issuer as specified in its charter)
|
Delaware |
11-2644611 |
|
(State
or other jurisdiction |
(IRS
Employer Identification No.) |
|
Of
incorporation or organization) |
|
| |
|
734 Walt
Whitman Rd., Melville, New York 11747
(Address
of principal executive offices)
(631)
421-5452
(Issuer's
telephone number)
Indicate
by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days. Yes [ X ]
No [ ]
APPLICABLE
ONLY TO CORPORATE ISSUERS
Indicate the number of shares outstanding of each of
the issuer’s class of common stock, as
of the latest practicable date: 13,897,858.
EXPLANATORY
NOTE
Item 3. Controls and Procedures and Item 6. are
amended in this Form 10-QSB/A
(a)
Evaluation of disclosure controls and procedures
An
evaluation of the effectiveness of the design and operation of the Company’s
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e) as of March 31, 2005 was carried out under the supervision and
with the participation of the Company’s management, including the President and
Chief Executive Officer and the Chief Financial Officer (“the Certifying
Officers”). Based on that evaluation, the Certifying Officers concluded that the
Company’s disclosure controls and procedures are effective.
Disclosure
controls and procedures are designed to ensure that information required to be
disclosed in our reports filed or submitted under the Securities Exchange Act is
recorded, processed, summarized and reported within the time periods specified
in the SEC’s rules and forms. Disclosure controls and procedures include,
without limitation, controls and procedures designed to ensure that information
required to be disclosed in our reports filed or submitted under the Securities
Exchange Act is accumulated and communicated to management, including our
President and Chief Financial Officer, as appropriate, to allow timely decisions
and timely reporting regarding required disclosure.
(b)
Changes in internal controls
There was
no change to the Company’s internal control over financial reporting during the
quarter ended March 31, 2005 that materially affected, or is reasonably likely
to materially affect, the Company’s internal control over financial
reporting.
BOVIE
MEDICAL CORPORATION
SIGNATURES:
In
accordance with the requirements of the Exchange Act, the registrant caused this
report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Bovie
Medical Corporation.
(Registrant)
Date: August 25,
2005
/s/Andrew
Makrides
Chief
Executive Officer - Andrew Makrides
/s/Andrew
Makrides
Acting
Chief Financial Officer - Andrew
Makrides